Nurix Therapeutics is a cash-burning clinical-stage biotechnology company heavily dependent on its bexobrutideg program, with a high short interest of 19% and a quality score of 1.8 far below acceptable thresholds, but recent analyst cluster activity and 63.7% upside to consensus target reflect speculative event-driven interest.
Thesis pillars
- Pipeline Concentration Bexobrutideg→Stable
- Analyst Cluster Sentiment Boost→Stable
- Cash Burning Below Quality Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Jan 28, 2026
Nurix Therapeutics, Inc. (NRIX) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $25.94. At $27.26 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $25.94 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: bexobrutideg; Near 52-week high (3.4% away).
Nurix Therapeutics develops targeted protein degradation medicines with three clinical-stage drug candidates targeting B-cell malignancies and solid tumors. The company has received $482 million in non-dilutive funding from collaborations with Gilead, Sanofi, and Pfizer, and is... Read more
Wait for pullback to $25.94. At $27.26 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $25.94 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: bexobrutideg; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Value play: 55% MoS with quality 8.5. | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Score 6.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Nurix Therapeutics, Inc.
About Nurix Therapeutics, Inc.
Nurix Therapeutics advances three wholly-owned clinical-stage drug candidates through its DEL-AI targeted protein degradation platform, with bexobrutideg entering a Phase 2 potentially pivotal CLL trial in October 2025 following FDA agreement on the 600 mg once-daily dose. The company had received $482 million in non-dilutive collaboration funding through November 30, 2025, and is eligible for up to $6.1 billion in potential milestones and royalties from partnerships with Gilead Sciences, Sanofi, and Pfizer.
Nurix generates revenue through collaboration agreements granting partners access to its DEL-AI discovery engine, retaining co-development, co-commercialization, and profit-sharing options in the United States for multiple drug candidates. Bexobrutideg (NX-5948) targets BTK in patients who have failed three prior lines of therapy — a covalent BTK inhibitor, a BCL2 inhibitor, and a non-covalent BTK inhibitor — the same triple-refractory population for which no approved standard of care exists. A second BTK program, zelebrudomide (NX-2127), is in Phase 1 dose escalation in aggressive B-cell lymphomas including DLBCL and MCL following a partial clinical hold resolved in August 2024. A third asset, NX-1607, an oral CBL-B inhibitor, is in Phase 1 across multiple solid tumor indications. Partnered programs include GS-6791/NX-0479, an IRAK4 degrader for which FDA cleared an IND in April 2025, and NX-3911, a STAT6 degrader that Sanofi licensed in June 2025. Manufacturing and clinical supplies are sourced through third-party contract manufacturers.
Show full overview
Bexobrutideg's Phase 2 DAYBreak trial, designed as a potentially pivotal study seeking Accelerated Approval in relapsed or refractory CLL patients, represents the company's most critical near-term binary event. The 10-K notes that no regulatory authority has approved any targeted protein degrader therapeutic, making this an unproven modality subject to additional regulatory scrutiny beyond established drug classes. Bexobrutideg received FDA Fast Track designation in CLL/SLL in January 2024 and EMA PRIME designation in November 2024 — regulatory milestones that may accelerate review timelines but do not reduce clinical evidence requirements.
See also: Healthcare · Biotechnology
From Nurix Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Nurix Therapeutics, Inc.
Latest news
- NEWS NRIX Stock Quote Price and Forecast - CNN — CNN neutral
- NEWS Nurix Therapeutics (NASDAQ:NRIX) Shares Climb 4.1% After Analyst Upgrade - MarketBeat — MarketBeat positive
- NEWS Why Did Nurix Therapeutics (NASDAQ:NRIX) Report USD 4.73 of EPS on USD 653 Million of Roche License Revenue? - kalkine.c — kalkine.ca positive
- NEWS NRIX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus — GuruFocus neutral
- NEWS What is HC Wainwright's Forecast for NRIX FY2026 Earnings? - MarketBeat — MarketBeat neutral
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebexobrutideg10-K Item 1A: 'substantially all of our efforts and financial resources ... the DAYBreak Phase 2 clinical trial evaluating bexobrutideg'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $25.94. At $27.26 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $25.94 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: bexobrutideg; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Value play: 55% MoS with quality 8.5. | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Target $30.02 (+10.1%), stop $24.12 (−13.0%), A.R:R 0.7:1. Score 6.4/10, moderate confidence.
Take-profit target: $30.02 (+10.1% upside). Target $30.02 (+10.1%), stop $24.12 (−13.0%), A.R:R 0.7:1. Stop-loss: $24.12.
Concentration risk — Pipeline: bexobrutideg; Near 52-week high (3.4% away); Consecutive earnings misses (3).
Nurix Therapeutics, Inc. trades at a P/E of 11.2 (forward -21.4). TrendMatrix value score: 6.8/10. Verdict: Buy (Wait for Entry).
20 analysts cover NRIX with a consensus score of 4.3/5. Average price target: $35.
What does Nurix Therapeutics, Inc. do?Nurix Therapeutics develops targeted protein degradation medicines with three clinical-stage drug candidates targeting...
Nurix Therapeutics develops targeted protein degradation medicines with three clinical-stage drug candidates targeting B-cell malignancies and solid tumors. The company has received $482 million in non-dilutive funding from collaborations with Gilead, Sanofi, and Pfizer, and is eligible for up to $6.1 billion in potential milestones and royalties.